NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
Clinical Trials
20 trialsNCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT06001762 2026-01-16
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07127315 2025-08-17
Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Helwan University
Completed
NCT03944434 2025-02-26
FACILE
Fondazione Sandro Pitigliani
Phase 2 Active not recruiting
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06346457 2024-04-04
Breast Cancer & Antiestrogenic Therapy & Brain
International Research Training Group 2804
Unknown
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT02221999 2023-08-29
SHPD002
RenJi Hospital
Phase 2/3 Active not recruiting
NCT05801705 2023-05-18
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT03058939 2019-04-22
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Withdrawn
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT01638247 2018-09-19
MALE
GBG Forschungs GmbH
Phase 3 Completed
NCT03543059 2018-06-01
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
Sun Yat-sen University
Unknown
NCT03397537 2018-01-17
Neoadjuvant Endocrine Therapy in Breast Cancer
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT02483767 2017-10-17
POF
Peking Union Medical College Hospital
Phase 3 Completed
NCT01311037 2011-12-13
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
King Faisal Specialist Hospital & Research Center
Unknown